The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 03, 2019

Filed:

Mar. 23, 2016
Applicant:

Ajou University Industry-academic Cooperation Foundation, Suwon-si, Gyeonggi-do, KR;

Inventors:

Yong Sung Kim, Suwon-si, KR;

Ye Jin Kim, Busan, KR;

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); A61K 9/127 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); C07K 19/00 (2006.01); G01N 33/53 (2006.01); A61K 47/50 (2017.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/705 (2013.01); A61K 9/127 (2013.01); A61K 47/50 (2017.08); C07K 19/00 (2013.01); G01N 33/53 (2013.01); G01N 33/57492 (2013.01); G01N 33/6845 (2013.01); G01N 33/6872 (2013.01); G01N 33/6893 (2013.01); A61K 38/00 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2319/30 (2013.01); G01N 2333/70596 (2013.01); G01N 2800/7014 (2013.01);
Abstract

A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.


Find Patent Forward Citations

Loading…